2.Management of Hypertriglyceridemia for Prevention of Cardiovascular Diseases.
Journal of Lipid and Atherosclerosis 2013;2(2):53-60
Hypertriglyceridemia has been considered as a risk factor for cardiovascular diseases. However, triglyceride levels are influenced by many clinical and lipid risk factors. When triglyceride levels are adjusted by these variables, the effect of hypertriglyceridemia as a cardiovascular risk factor becomes minimal or negligible. Therefore, the association of hypertriglyceridemia with cardiovascular diseases is uncertain. The effect of triglyceride-lowering drugs on cardiovascular diseases is also unclear. These drugs failed to reduce cardiovascular events in relatively high risk patients with variable lipid profiles. However, subgroup analysis showed the cardioprotective effects in selected patients. It is clinically important whether a patient with hypertriglyceridemia should be treated with drug therapy or not. This paper discusses this issue based on limited data of published reports.
Cardiovascular Diseases*
;
Drug Therapy
;
Humans
;
Hypertriglyceridemia*
;
Risk Factors
;
Triglycerides
3.Research on Collateral-unblocking Medicines for Cardiovascular Diseases under the Guidance of Vessels Collateral Theory.
Cong WEI ; Li-ping CHANG ; Zhen-hua JIA
Chinese Journal of Integrated Traditional and Western Medicine 2015;35(12):1513-1516
"Vessels Collateral Theory", as the inherit and development of "blood vessels" in Huangdi Neijing, is a systematic system by integrating severe vascular diseases. In this article, by taking cardiovascular diseases (CVD) as a cut-in point, roles of "minute collateral-microvascular" lesions in the occurrence and development of CVD were further explored. The interventional effect of collateral-unblocking medicines under the guidance of Vessels Collateral Theory was also in-depth explored, hoping to leading Chinese medical prevention and treatment of CVD.
Cardiovascular Diseases
;
drug therapy
;
Humans
;
Medicine, Chinese Traditional
;
Research
6.Progress in researches on the pharmaceutical mechanism and clinical application of Ginkgo Biloba extract on various kinds of diseases.
Guo-xia WANG ; Fu-liang CAO ; Jun CHEN
Chinese journal of integrative medicine 2006;12(3):234-239
Progress made over the pharmaceutical mechanism and clinical application of Ginkgo Biloba extract (GBE) on various kinds of diseases were reviewed in this paper. The effective elements contained in GBE are mainly kinds of Ginkgo flavonoid and Ginkgolide, which have marked protective effects on cardio-cerebral vascular and central nerve systems. In clinical practice, it is applied mostly in treatment of cardio-cerebral vascular diseases. Also it shows apparent effects in the treatment processes of some other diseases as an adjuvant, and therefore, has been gradually accepted by the medical circle in the world, proving to be a medicine of wide prospect in development and application.
Cardiovascular Diseases
;
drug therapy
;
Diabetes Mellitus
;
drug therapy
;
Ginkgo biloba
;
Humans
;
Nervous System Diseases
;
drug therapy
;
Plant Extracts
;
therapeutic use
7.Research progress in pharmacological effectsand mechanism of Fel Ursi against cardiovascular and cerebrovascular diseases.
Li-Dan ZHU ; Jie LIAO ; Xiao-Yan LU ; Xiao-Hui FAN
China Journal of Chinese Materia Medica 2023;48(23):6307-6314
Fel Ursi is a dried product obtained from the gallbladder of Ursidae animals, such as Selenarctos thibetanus or Ursus arctos, through gallbladder surgery for bile drainage. It is one of the rare animal medicinal materials in China and is known for its therapeutic effects, including clearing heat, removing toxins, extinguishing wind, relieving spasms, clearing the liver, and improving vision. Research has also found that Fel Ursi has pharmacological effects against cardiovascular and cerebrovascular diseases, such as anti-inflammatory, anti-apoptotic, and antioxidant stress properties. Recently, numerous studies have confirmed the close relationship between cardiovascular and cerebrovascular diseases and the gut microbiota as well as gut metabolites. Fel Ursi contains bile acid components that may have bidirectional regulatory effects on the gut microbiota and gut metabolites. This aspect could represent a potential therapeutic pathway for Fel Ursi in the treatment of cardiovascular and cerebrovascular diseases. This article comprehensively summarized relevant literature in China and abroad, reviewed the research progress on the pharmacological effects of Fel Ursi against cardiovascular and cerebrovascular diseases, and explored the impact of Fel Ursi on gut microbiota and gut metabolites, thereby aiming to provide references for further in-depth research and clinical application of Fel Ursi.
Animals
;
Cerebrovascular Disorders/drug therapy*
;
Bile Acids and Salts
;
Lung
;
Liver
;
Ursidae
;
Cardiovascular Diseases/drug therapy*
8.Pharmacotherapy of Diabetes Focused on Stroke
Young Sang LYU ; Jin Hwa KIM ; Sang Yong KIM
Journal of the Korean Neurological Association 2019;37(3):235-250
Cardiovascular disease, including stroke, is one of the major causes of death in diabetes. Numerous studies have long suggested reducing macrovascular complication such as ischemic vascular disease through intensive glycemic control, but none was successful proving the effect of glycemic control. Recently, new possibilities in cardiovascular disease reduction have been proposed through cardiovascular safety trials of newly developed anti-hyperglycemic agents. The purpose of this review is to introduce the traditional and newly developed anti-diabetic medications and review their effects regarding cardiovascular outcomes mainly focusing on stroke.
Cardiovascular Diseases
;
Cause of Death
;
Diabetes Complications
;
Diabetes Mellitus
;
Drug Therapy
;
Hypoglycemic Agents
;
Stroke
;
Vascular Diseases
9.Management of menopausal syndrome in women with dyslipidemia.
Yang Mei LI ; Xun LEI ; Li Li YU
Chinese Journal of Preventive Medicine 2023;57(11):1908-1914
The prevalence of dyslipidemia is increased in postmenopausal women due to dysregulation of lipid metabolism and deficiency of estrogen levels. At the same time, some postmenopausal women also have menopausal syndromes such as vasomotor symptoms, physical physiology, mental psychology, and urogenital tract atrophy. Menopausal hormone therapy is the most effective measure to alleviate menopausal syndrome. And initiating MHT in early menopause can reduce cardiovascular damage. However, menopausal hormone therapy can also bring the risk of thromboembolic diseases such as venous embolism, myocardial infarction and stroke. Different drug regimens have different effects on lipid metabolism. Women with menopausal syndrome should take individualized treatment plans for different types of dyslipidemia. Therefore, this article reviews the management and treatment of menopausal syndrome in women with dyslipidemia, so as to provide a reference for personalized management of dyslipidemia in postmenopausal women.
Female
;
Humans
;
Menopause
;
Estrogen Replacement Therapy
;
Cardiovascular Diseases/epidemiology*
;
Estrogens/pharmacology*
;
Dyslipidemias/drug therapy*
10.Management of menopausal syndrome in women with dyslipidemia.
Yang Mei LI ; Xun LEI ; Li Li YU
Chinese Journal of Preventive Medicine 2023;57(11):1908-1914
The prevalence of dyslipidemia is increased in postmenopausal women due to dysregulation of lipid metabolism and deficiency of estrogen levels. At the same time, some postmenopausal women also have menopausal syndromes such as vasomotor symptoms, physical physiology, mental psychology, and urogenital tract atrophy. Menopausal hormone therapy is the most effective measure to alleviate menopausal syndrome. And initiating MHT in early menopause can reduce cardiovascular damage. However, menopausal hormone therapy can also bring the risk of thromboembolic diseases such as venous embolism, myocardial infarction and stroke. Different drug regimens have different effects on lipid metabolism. Women with menopausal syndrome should take individualized treatment plans for different types of dyslipidemia. Therefore, this article reviews the management and treatment of menopausal syndrome in women with dyslipidemia, so as to provide a reference for personalized management of dyslipidemia in postmenopausal women.
Female
;
Humans
;
Menopause
;
Estrogen Replacement Therapy
;
Cardiovascular Diseases/epidemiology*
;
Estrogens/pharmacology*
;
Dyslipidemias/drug therapy*